DE69023637D1 - Bakterien transformiert mit Expressionsplasmiden, die für den menschlichen NEUROTHROPHEN WIMPER FAKTOR (h-CNTF) kodieren, ihre Verwendung in der Herstellung von h-CNTF, Antikörper gegen h-CNTF und die Anwendung von h-CNTF in medizischer Behandlung. - Google Patents
Bakterien transformiert mit Expressionsplasmiden, die für den menschlichen NEUROTHROPHEN WIMPER FAKTOR (h-CNTF) kodieren, ihre Verwendung in der Herstellung von h-CNTF, Antikörper gegen h-CNTF und die Anwendung von h-CNTF in medizischer Behandlung.Info
- Publication number
- DE69023637D1 DE69023637D1 DE69023637T DE69023637T DE69023637D1 DE 69023637 D1 DE69023637 D1 DE 69023637D1 DE 69023637 T DE69023637 T DE 69023637T DE 69023637 T DE69023637 T DE 69023637T DE 69023637 D1 DE69023637 D1 DE 69023637D1
- Authority
- DE
- Germany
- Prior art keywords
- cntf
- nucleic acid
- acid sequences
- relates
- variety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40817289A | 1989-09-15 | 1989-09-15 | |
US42951789A | 1989-10-31 | 1989-10-31 | |
US57065190A | 1990-08-20 | 1990-08-20 | |
PCT/US1990/005241 WO1991004316A2 (en) | 1989-09-15 | 1990-09-14 | Ciliary neurotrophic factor |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69023637D1 true DE69023637D1 (de) | 1995-12-21 |
DE69023637T2 DE69023637T2 (de) | 1996-10-17 |
Family
ID=27410749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69023637T Expired - Fee Related DE69023637T2 (de) | 1989-09-15 | 1990-09-14 | Bakterien transformiert mit Expressionsplasmiden, die für den menschlichen NEUROTHROPHEN WIMPER FAKTOR (h-CNTF) kodieren, ihre Verwendung in der Herstellung von h-CNTF, Antikörper gegen h-CNTF und die Anwendung von h-CNTF in medizischer Behandlung. |
Country Status (11)
Country | Link |
---|---|
US (1) | US6602687B1 (de) |
EP (1) | EP0448707B1 (de) |
JP (2) | JPH05199879A (de) |
AT (1) | ATE130365T1 (de) |
AU (1) | AU705371B2 (de) |
CA (1) | CA2040404A1 (de) |
DE (1) | DE69023637T2 (de) |
ES (1) | ES2084045T3 (de) |
IE (1) | IE903130A1 (de) |
LV (1) | LV10308A (de) |
WO (1) | WO1991004316A2 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5141856A (en) * | 1989-01-05 | 1992-08-25 | Synergen, Inc. | Expression of purified ciliary neurotrophic factor |
AT405835B (de) * | 1989-01-05 | 1999-11-25 | Synergen Inc | Aufgereinigter ziliärer neurotropher faktor |
IL98304A (en) * | 1990-06-01 | 2008-08-07 | Regeneron Pharma | The ciliary neurotrophic factor receptor |
IT1247150B (it) * | 1991-01-21 | 1994-12-12 | Fidia Spa | Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli. |
AU675409B2 (en) * | 1991-07-10 | 1997-02-06 | Regeneron Pharmaceuticals, Inc. | Methods of treatment of motor neuron diseases using members of the BDNF/NT-3/NGF family of molecules |
JPH07500725A (ja) * | 1991-07-23 | 1995-01-26 | シンテックス−シナージェン ニューロサイエンス ジョイント ベンチャー | 組換え毛様体向神経因子およびc−末端切断毛様体向神経因子の精製ならびに末梢神経障害の処置方法 |
US5593857A (en) * | 1991-08-23 | 1997-01-14 | Scios Inc. | Production of homogeneous truncated CNTF |
CA2119580A1 (en) * | 1991-10-01 | 1993-04-15 | George Cachianes | Production of gpa neurotrophic factor |
JPH07503128A (ja) * | 1991-11-11 | 1995-04-06 | フィディーア・ソシエタ・ペル・アチオニ | ヒト毛様体ニューロン親和性因子の先端欠失型および突然変異タンパク質型の合成と精製 |
WO1994003199A1 (en) * | 1992-08-04 | 1994-02-17 | Regeneron Pharmaceuticals, Inc. | Method of enhancing differentiation and survival of neuronal precursor cells |
WO1994008026A1 (en) * | 1992-09-25 | 1994-04-14 | Rhone-Poulenc Rorer S.A. | Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain |
US6472178B1 (en) | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
WO1994017818A1 (en) * | 1993-02-08 | 1994-08-18 | The Syntex-Synergen Neuroscience Joint Venture | Methods for treating amyotrophic lateral sclerosis with cntf |
ZA941729B (en) * | 1993-03-12 | 1994-10-13 | Max Planck Gesellschaft | Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5). |
FR2705361B1 (fr) * | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
EP0632008B1 (de) | 1993-06-01 | 1998-02-04 | Ono Pharmaceutical Co., Ltd. | Pentansäurederivate |
US6143714A (en) * | 1994-10-24 | 2000-11-07 | Regeneron Pharmaceuticals, Inc. | Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons |
ATE386811T1 (de) | 1996-04-05 | 2008-03-15 | Novartis Vaccines & Diagnostic | Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen |
FR2753379B1 (fr) * | 1996-09-13 | 1998-10-30 | Rhone Poulenc Rorer Sa | Methode de traitement de la sclerose laterale amyotrophique |
IT1288388B1 (it) | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
US6313089B1 (en) | 1997-08-20 | 2001-11-06 | Duke University | Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use |
EP0999270A1 (de) * | 1998-10-09 | 2000-05-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Verfahren zur Regulierung der SMN-Genexpression |
WO2001089550A2 (en) * | 2000-05-24 | 2001-11-29 | Regeneron Pharmaceuticals, Inc. | Use of ciliary neurotrophic factor |
ES2364037T3 (es) * | 2001-12-10 | 2011-08-23 | Novartis Ag | Métodos de tratamiento de psicosis y esquizofrenia basados en polimorfismos del gen del cntf. |
JP2005073592A (ja) * | 2003-09-01 | 2005-03-24 | Yukiguni Maitake Co Ltd | マイタケ由来のレクチンをコードする遺伝子 |
US8592374B2 (en) | 2007-03-16 | 2013-11-26 | Research Foundation For Mental Hygiene, Inc. | Neurotrophic peptides |
EP2009103A1 (de) | 2007-03-16 | 2008-12-31 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Neurotrophische Peptide |
JP6495830B2 (ja) * | 2013-12-11 | 2019-04-03 | 住友化学株式会社 | 毛様体周縁部様構造体の製造法 |
CA3104472A1 (en) * | 2018-06-19 | 2019-12-26 | Cella Therapeutics, Llc | Drug delivery systems comprising active pharmaceutical ingredients and a sustained delevery component |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4923696A (en) | 1987-05-04 | 1990-05-08 | Baylor College Of Medicine | Method to prepare a neurotrophic composition |
US5011914A (en) | 1989-01-05 | 1991-04-30 | Collins Franklin D | Purified ciliary neurotrophic factor |
US4997929A (en) | 1989-01-05 | 1991-03-05 | Synergen, Inc. | Purified ciliary neurotrophic factor |
US5141856A (en) * | 1989-01-05 | 1992-08-25 | Synergen, Inc. | Expression of purified ciliary neurotrophic factor |
EP0463082A1 (de) * | 1989-03-15 | 1992-01-02 | The Regents Of The University Of California | Reinigung von cntf |
CN1057295A (zh) * | 1990-03-14 | 1991-12-25 | 菲迪安股份有限公司 | 人睫状神经元营养因子,编码该因子的dna序列,以及以重组技术生产该因子 |
-
1990
- 1990-08-29 IE IE313090A patent/IE903130A1/en unknown
- 1990-09-14 EP EP90917018A patent/EP0448707B1/de not_active Expired - Lifetime
- 1990-09-14 AU AU67402/90A patent/AU705371B2/en not_active Ceased
- 1990-09-14 AT AT90917018T patent/ATE130365T1/de not_active IP Right Cessation
- 1990-09-14 DE DE69023637T patent/DE69023637T2/de not_active Expired - Fee Related
- 1990-09-14 WO PCT/US1990/005241 patent/WO1991004316A2/en active IP Right Grant
- 1990-09-14 CA CA002040404A patent/CA2040404A1/en not_active Abandoned
- 1990-09-14 JP JP90246008A patent/JPH05199879A/ja active Pending
- 1990-09-14 ES ES90917018T patent/ES2084045T3/es not_active Expired - Lifetime
-
1992
- 1992-05-08 US US07/883,630 patent/US6602687B1/en not_active Expired - Lifetime
-
1993
- 1993-05-31 LV LV930441A patent/LV10308A/xx unknown
-
2001
- 2001-04-25 JP JP2001128506A patent/JP2001354697A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ATE130365T1 (de) | 1995-12-15 |
JP2001354697A (ja) | 2001-12-25 |
EP0448707A4 (en) | 1992-11-19 |
EP0448707B1 (de) | 1995-11-15 |
ES2084045T3 (es) | 1996-05-01 |
CA2040404A1 (en) | 1991-03-16 |
LV10308A (lv) | 1994-10-20 |
JPH05199879A (ja) | 1993-08-10 |
WO1991004316A3 (en) | 1991-04-18 |
AU6740290A (en) | 1991-04-18 |
WO1991004316A2 (en) | 1991-04-04 |
DE69023637T2 (de) | 1996-10-17 |
AU705371B2 (en) | 1999-05-20 |
US6602687B1 (en) | 2003-08-05 |
EP0448707A1 (de) | 1991-10-02 |
IE903130A1 (en) | 1991-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69023637D1 (de) | Bakterien transformiert mit Expressionsplasmiden, die für den menschlichen NEUROTHROPHEN WIMPER FAKTOR (h-CNTF) kodieren, ihre Verwendung in der Herstellung von h-CNTF, Antikörper gegen h-CNTF und die Anwendung von h-CNTF in medizischer Behandlung. | |
DE3855921D1 (de) | Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein | |
DE69634301D1 (de) | Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf) | |
NO905264D0 (no) | Fremgangsmaate for fremstilling av biologisk aktivt protein | |
ATE256475T1 (de) | Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten | |
DE69333229T2 (de) | Verfahren zur reinigung eines neurotrophen faktors aus pigmentiertem retinalen epithelgewebe | |
FI912104A0 (fi) | Neurotrofisk faktor haerledd fraon hjaerna. | |
DE59003771D1 (de) | Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte. | |
DE59303365D1 (de) | Derivate in der vitamin d-reihe mit modifikationen in der 20 position, verfahren zu ihrer herstellung, zwischenprodukte für dieses verfahren, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln | |
EP0213499A3 (de) | Aminosäure-Derivate, Verfahren zu ihrer Herstellung und Verwendung | |
ATE192495T1 (de) | Carboxypeptidase-ähnliches protein aus knochen und verfahren zur dessen herstellung | |
ATE15897T1 (de) | Ausgangsprodukte zur herstellung von cephalosporinen und verfahren zu ihrer herstellung. | |
DE19681032D2 (de) | Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen | |
EP0458673B1 (de) | Wachstumsinhibierender Faktor und für den wachstumsinhibierenden Faktor kodierender cDNS | |
ATE335759T1 (de) | Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind. | |
ATE208420T1 (de) | Protein des cadherin-typs aus knochen und verfahren zur herstellung | |
EP0324447A3 (de) | Mittel und Verfahren zur Herstellung eines rekombinanten, menschlichen Interleukin-1 alpha-Polypeptides | |
GR900100691A (el) | Νευροτροφικός παράγοντας ακτινωτού. | |
DE60002552D1 (de) | Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen | |
EP0895994A3 (de) | Sulfonamid-substituierte Pyranopyridine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament | |
DE69424415T2 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit | |
ATE186640T1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen | |
DE3861866D1 (de) | Aspoxicillin enthaltende medizinalzubereitung, ein verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels. | |
ATE163424T1 (de) | Neue 17-(3-imino-2-alkyl-propenyl)-5beta-14beta- androstanderivate, zur behandlung von kardiovaskulären erkrankungen, ein verfahren zu ihrer herstellung und pharmazeutische präparate davon | |
DE2539800C3 (de) | Verfahren zur Herstellung einer für die intravenöse Anwendung geeigneten Gammaglobulinlösung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENS |
|
8327 | Change in the person/name/address of the patent owner |
Owner name: REGENERON PHARMACEUTICALS, INC., TARRYTOWN, N.Y., |
|
8339 | Ceased/non-payment of the annual fee |